Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.

Leukemia - 1 Dec 2020

Eisfeld Ann-Kathrin, Kohlschmidt Jessica, Mims Alice, Nicolet Deedra, Walker Christopher J, Blachly James S, Carroll Andrew J, Papaioannou Dimitrios, Kolitz Jonathan E, Powell Bayard E, Stone Richard M, de la Chapelle Albert, Byrd John C, Mrózek Krzysztof, Bloomfield Clara D

Abstract excerpt

The European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) have become an important tool to assess patients' prognosis and guide treatment. We tested the prognostic impact of the 2017 ELN classification in a large cohort of 863 AML patients aged <60 years similarly treated on Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology studies. Based on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to WT1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nucleophosmin

Share to Prognosis

Share to Risk Factors

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 32461631
DOI: 10.1038/s41375-020-0872-3
PMCID: PMC7882079

Genes

ELN
NPM1
BCOR
DNMT3A
FLT3
SETBP1
WT1
ZRSR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.PMID 32461631Read ↗

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.Semantic proximity Read ↗

Updates in molecular genetics of acute myeloid leukemia.Semantic proximity Read ↗

Advances in therapeutic options for newly diagnosed, high-risk AML patientsSemantic proximity Read ↗

Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China.Semantic proximity Read ↗

Unified classification and risk-stratification in Acute Myeloid LeukemiaSemantic proximity Read ↗

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.Semantic proximity Read ↗

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.Semantic proximity Read ↗

Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid LeukemiaSemantic proximity Read ↗

Genomic Classification and Prognosis in Acute Myeloid Leukemia.Semantic proximity Read ↗

Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.